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Abstract Alzheimer’s disease and other age-related neurodegenerative disorders are 
associated with deterioration of the noradrenergic locus coeruleus (LC), a probable trigger for 
mood and memory dysfunction. LC noradrenergic neurons exhibit particularly high levels of 
somatostatin binding sites. This is noteworthy since cortical and hypothalamic somatostatin 
content is reduced in neurodegenerative pathologies. Yet the role of a somatostatin signal-
deficit in the maintenance of noradrenergic projections remains unknown. Here, we deployed 
tissue microarrays, immunohistochemistry, quantitative morphometry and mRNA profiling in 
a cohort of Alzheimer’s and age-matched control brains in combination with genetic models 
of somatostatin receptor deficiency to establish causality between defunct somatostatin 
signalling and noradrenergic neurodegeneration. In Alzheimer’s disease, we found 
significantly reduced somatostatin protein expression in the temporal cortex, with aberrant 
clustering and bulging of tyrosine hydroxylase-immunoreactive afferents. As such, 
somatostatin receptor 2 (SSTR2) mRNA was highly expressed in the human LC, with its 
levels significantly decreasing from Braak stages III/IV and onwards, i.e. a process preceding 
advanced Alzheimer’s pathology. The loss of SSTR2 transcripts in the LC neurons was 
selective, since tyrosine hydroxylase, dopamine ß-hydroxylase, galanin or galanin receptor 3 
mRNAs remained unchanged. We modeled these pathogenic changes in Sstr2-/- mice and, 
unlike in Sstr1-/- or Sstr4-/- genotypes, they showed selective, global and progressive 
degeneration of their central noradrenergic projections. However, neuronal perikarya in the 
LC were found intact until late adulthood (<8 months) in Sstr2-/- mice. In contrast, the 
noradrenergic neurons in the superior cervical ganglion lacked SSTR2 and, as expected, the 
sympathetic innervation of the head region did not show any signs of degeneration. Our 
results indicate that SSTR2-mediated signaling is integral to the maintenance of central 
noradrenergic projections at the system level, and that early loss of somatostatin receptor 2 
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function may be associated with the selective vulnerability of the noradrenergic system in 
Alzheimer’s disease. 
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Introduction  
Locus coeruleus (LC) is a key node in the mammalian brain sending projections to virtually 
all parts of the central nervous system [8,40,72,47]. Its principle transmitter is noradrenaline 
(NA) [26]. The NA circuitry is involved in multiple physiological processes, including 
arousal, wakefulness, memory and motor functions as well as stress and mood regulation 
[39,9,18,73,17,11,97]. Several clinical studies indicate degenerative changes of the central 
noradrenergic system in Alzheimer’s disease [12,22,44,65,103] as well as in Parkinson’s 
disease and in Down’s syndrome [44]. Impairment of this monoamine system is also involved 
in major depressive disorder [93,18]. In fact, in Alzheimer’s disease neuronal loss is more 
pronounced in LC than in the nucleus basalis of Meynert [119]. Recently, pre-tangle 
formation was found in the LC of young individuals, supporting the hypothesis that 
LC/subcoeruleus represents an early starting point for Alzheimer’s disease pathology, even 
preceding the occurrence of cortical lesions [10,13,15]. Nevertheless, the cause(s) and 
underlying mechanism(s) of the early LC degeneration in Alzheimer’s disease remain unclear. 
 In addition to direct functional deficits, NA lesions may induce amyloid formation via 
microglial inflammatory processes [52] and via loss of BDNF production or brain 
microvascular impairments [48,85]. The currently used mouse models of Alzheimer’s disease 
(transgenic mice expressing mutant forms of amyloid precursor protein (APP), presenilins and 
tau, singly or in combination), however, exhibit at most mild LC degeneration or no 
degeneration at all [115,45]. In contrast, a selective. chemical lesion of LC in APP-mutant 
mice induced by DSP4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride)  
exacerbates the Aβ plaque load as well as cholinergic and spatial memory deficits [49,115]. 
Also, when Ear2-/- mice with an early noradrenergic deficit (Ear2 is an orphan nuclear 
receptor necessary for the development of LC neurons in mice) were crossed with APP/PS1 
mice, they exhibited a significantly more severe impairment of spatial memory and 
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hippocampal long-term potentiation than mice with either APP/PS1 mutation or loss of Ear2 
alone [60]. Thus, these transgenic animal models are useful tools to study the consequences of 
noradrenergic impairment in experimental models of Alzheimer’s disease but lack the 
inherent capacity to reveal candidate mechanism(s) underlying LC vulnerability. 
 Another, early established neurochemical hallmark of Alzheimer’s disease is a 
substantial deficit of somatostatin (SST) in cortical areas and in the hypothalamus 
[20,76,27,58,89]. SST is a regulatory peptide originally discovered as the hypothalamic factor 
inhibiting growth hormone release [16,107] and subsequently found to have wide distribution 
and multiple functions in the brain [34,112]. SST acts via six subtypes of G-protein-coupled 
receptors, of which SSTR2(a) is one of the most abundant in the brain [54,112,101]. In 
Alzheimer’s disease SST was the most consistently reduced among all neuropeptides so far 
examined [20]. Likewise, SSTR2 mRNA expression was significantly decreased in the frontal 
and temporal cortices [42,59]. Amyloid plaques show immunoreactivity for SST [74]. Also, 
polymorphisms of the SST gene are risks factors for Alzheimer’s disease [111,117], albeit not 
confirmed in genome-wide association studies (GWAS). SST regulates the metabolism of Aβ 
through increasing neprylisin activity [90]. SST deficits were also detected in major 
depressive- and bipolar disorders [64]. Moreover, SSTR2/SSTR3 modulation of monoamine 
systems may induce antidepressant effects in rats [32,33]. Results on SST impairments in 
Alzheimer’s disease mouse models are not consistent [53,91]. However, one study on 
APPxPS1 mice reported an early decrease of SST expression and selective loss of SST-
expressing interneurons in the hippocampus [84], which was also described in human post 
mortem samples [58,27]. These observations could provide explanations for the intimate 
correlation of the decrease in SST levels and cognitive deficit in Alzheimer’s disease [36].  
 Interestingly, the density of SST binding sites is very high in the LC both in the rodent 
[35,41] and human brain [21], and SST has strong inhibitory effect on LC neurons in vitro 
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[68,79,55,23] and in vivo [104]. However, less attention has been paid to a potential 
contribution of the well-established SST impairment to the well-defined noradrenergic deficit 
in neurodegenerative disorders. 
 To fill this gap, we first examined the expression of SSTR2 in LC samples from 
Alzheimer’s disease cases and age-matched control subjects and found a decrease already in 
individuals with intermediate Alzheimer’s disease neuropathological changes, Braak III-IV 
stage. Then we studied the potential role of SST receptors in the maintenance of the 
noradrenergic system in transgenic animal strains. Thus, the morphology and neurochemistry 
of neurocircuitries were examined in Sstr1, Sstr2 and Sstr4 knockout animals with special 
attention to the monoaminergic systems. We show that the deletion of Sstr2, but not the other 
two SST receptors, results in a selective, global and progressive noradrenergic axonal 
degeneration.  
 
Materials and experimental procedures 
Detailed descriptions of human brains, Sstr knockout/LacZ-knockin mice strains and methods 
are provided in the Supplementary Information (SI). 
Immunohistochemistry on perfused human brains  
Human brains (N = 2; Suppl. Table 1) were obtained from the Department of Pathology, 
Szent Borbála Hospital, Tatabánya, Hungary. All procedures were approved by the Regional 
and Institutional Committee of Science and Research Ethics of Scientific Council of Health 
(ETT TUKEB 31443/2011/EKU, 518/PI/11, Hungary) and were in agreement with the 
Declaration of Helsinki.  
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Brains were removed 4 hours after death. Both internal carotid and vertebral arteries 
were cannulated, the brains were perfused as described [105]. Double-immunostaining 
procedure, confocal analysis and micrograph production were performed as described for 
animal tissue. 
Quantitative PCR on human LC micro-punch samples 
Pieces of frozen human brainstems were obtained from the Human Tissue Bank, Semmelweis 
University, Hungary (HBTB, ethical permission numbers: 6008/8/2002/ETT and 
32/1992/TUKEB). HBTB is a member of the BrainNet II Europe consortium. Procedures 
were in agreement with the Declaration of Helsinki. Neuropathological and histochemical 
examination of all brains, including classification of amyloid-β plaque burden, tau pathology 
and synuclein pathology was performed as described in the SI. Brains with Alzheimer’s 
disease Braak stage V-VI (N=7), with intermediate Alzheimer’s disease neuropathologic 
changes (Braak stage III-IV) (N=5) and age-matched controls with no neurodegenerative 
alterations and with no signs of clinical neuropsychiatric disease (N=9) were selected (Suppl. 
Table 2).  
During the micro-punch procedure, 1.0-1.5 mm thick coronal sections were cut at the 
level of LC and 4-6 tissue pellets were collected bilaterally with the application of 0.7 mm 
inside diameter microdissection needles (two from each coronal section) and kept frozen at 
minus 70oC pending analysis. 
 Total RNA from punched LC samples was extracted using the RNeasy Mini kit 
(Qiagen, Sollentuna, Sweden). TaqMan assay for tyrosine hydroxylase (TH 
(Hs00165941_m1) was purchased from Applied Biosystems (Carlsbad, CA) and the 
amplification reaction was carried out using TaqMan assay master mix (Applied Biosystems). 
All other primers were purchased from Sigma-Aldrich (Suppl. Table 3). Gene expression was 
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measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR) on an 
Applied Biosystems 7000 Real-Time PCR system. Relative fold changes were calculated by 
using the comparative CT method (2-∆∆CT). 
Tissue microarray (TMA) on human samples 
Formalin fixed brains were obtained from the Dutch Brain Bank (NBB, ethical permission no. 
EPN 2013/474-31/2). Procedures were in agreement with the Declaration of Helsinki. 
Detailed neuropathological examination of all brains was performed as described in the SI. 
A TMA block containing temporal cortex samples from Alzheimer’s disease subjects 
(N=7, Braak stage VI) and 9 age-matched controls (Suppl. Table 4) was constructed [56]. 
TMA slides were triple stained sequentially on a BOND-RX autostainer (Leica Microsystems, 
Wetzlar, Germany) for tyrosine hydroxylase (TH) or SST, amyloid-β and tau-PHF using 
tyramide signal amplification (TSA) method [1]. Slides were scanned on the VSlide scanning 
system (Metasystems, Alltlussheim, Germany) using 20x objectives and appropriate filter 
sets. Immunostaining for SST, amyloid-β and tau-PHF was quantified by densitometry with 
the Image J 1.37v software (1.37v, NIH, MD). 
Transgenic animals  
Experiments were performed on (i) 2-week and 1-, 2-, 4- and 8-month-old male homozygote 
Sstr2 knockout/LacZ knockin mice (Sstr2-/-) [5,6], (ii) 4-month-old male homozygote Sstr1 
knockout/LacZ knockin mice (Sstr1-/-) [61], (iii) 8-month-old male Sstr4 knockout/LacZ 
knockin mice (Sstr4-/-) [51] and on three 15-month-old male homozygous TgAPParc 
transgenic mice  and on their wild-type littermates (WTs) [87,88]. Experimental procedures 
were approved by the local ethical committee (Stockholms norra djurförsöksetiska nämnd, 
N171-172/11), and conformed to the European Communities Council Directive #86/609/EEC 
and the "Principles of laboratory animal care" (NIH publication No. 86-23, revised 1985). 
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Particular care was taken to minimize the number of animals and their suffering throughout 
the experiments. 
Fluorescence immunohistochemistry and microscopy/confocal analysis of mice 
 Mice were transcardially perfused with Zamboni fixative [28]. Sections were 
incubated overnight with primary antibodies (Table S5A) and processed using a commercial 
immunostaining kit (PerkinElmer Life Science, Boston, MA) based on tyramide signal 
amplification [1]. Numerous immunostained sections were sequentially double-stained with 
additional antibodies (Suppl. Table 5a–b) and examined with a Zeiss LSM 510 Meta 
confocal-system installed on a Zeiss Axioplan 2 microscope. 
Morphometry 
Cell body counting and determination of mean somatic surface area  
For each animal (8-month-old, N=3), 4 sections, immunostained for TH, counterstained with 
nuclear marker TO-PRO®-3, were analyzed at four different rostro-caudal levels of the LC. 
The number of TH-positive(+) cells/mm2 and somatic surface area of each neuron (µm2/cell) 
were measured using the Image J 1.37v software. Altogether 1,014 cells from Sstr2-/- 
(338±93/animal) and 989 cells (329±10/animal) from WT were examined. 
Densitometry of TH+ fibers and counting of enlarged varicosities and fiber clusters  
Mouse brain coronal sections (Bregma -5 to -4) from two-week, 1-, 2-, 4- and 8-month-old 
WT and Sstr2-/- animals (N=3-5), immunostained for TH, were captured on a Vslide scanning 
microscope (Metasystems). The number of ‘single swollen varicosities/intervaricose 
connections’ and ‘aberrant fiber clusters’/mm2 were determined in unilateral fronto-parietal 
cortices as described before [3]. A detailed description of these aberrant structures is reported 
in the Results and Fig. 7, Suppl. Fig. 2, legends). To determine the TH+ fiber density, we 
applied a 1-pixel algorithm using the Image J 1.37v in micrographs.  
Semiquantitative score of aberrant noradrenergic structures  
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A four-grade score was applied at numerous rostro-caudal levels (Table 1, legend) of three 4-
month- and three 8-month-old brains [immunostained for the NA/norepinephrine transporter 
(NET)]. 
Quantitative in situ hybridization (qISH) 
Mice (4-month-old, N=5/genotype) were decapitated and the brains rapidly dissected and 
snap-frozen. Antisense oligoprobes (TH, galanin), complementary or highly homologous to 
the mouse mRNA sequence, were synthesized by CyberGene AB (Huddinge, Sweden). The 
oligonucleotides were radioactively labeled with 33P, and sections were hybridized as 
described [92] and dipped in Kodak NTB-2 emulsion (Kodak, Rochester, NY). The transcript 
levels for TH and galanin expression in LC were quantified using an image analysis system 
(see SI). The number of silver grains was measured over the cell bodies with the Image J 
1.37v software.  
HPLC measurement of monoamines  
Mice (2-week and 4-month-old, N=5/genotype) were decapitated and fronto-parietal cortex, 
caudate-putamen and dorsal hippocampus samples were dissected and homogenized. 
Concentrations of NA, dopamine (DA), serotonin (5-hydroxytryptamine, 5-HT) were 
determined by HPLC as described [57]. The chromatograms were recorded and integrated by 
use of the computerized data acquisition system Clarity (DataApex, Prag, Czeck Republic).  
Statistical analyses 
One-way ANOVA and Fisher post-hoc tests were applied for human qPCR studies. Student’s 
t-test for independent samples was applied for the evaluation of densitometry on human TMA 
slides. One- and two-way ANOVA (quantification of aberrant fiber structures, fiber density 
measurements, respectively) and Tukey’s post-hoc test; three-way ANOVA and Tukey-test 
(HPLC measurements) and Student’s t-test for independent samples (qISH, cell body or 
somatic surface area, HPLC) were applied for animal studies. All data were evaluated with 
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acceptable levels of significance set at P < 0.05 using Statistica® 7 software. All variables, 
numerical data of ANOVA F/df and main effect P values are reported in Suppl. Tables 6-7.  
 
Results 
Somatodendritic localization of SSTR2a in the human LC 
To determine the precise localization of SSTR2 in the LC region, perfused non-
neurodegenerative human brainstems were studied. Prominent somatodendritic SSTR2a 
localization was found in many LC noradrenergic (TH-immunoreactive, IR) neurons in both 
examined human brainstems but not in other nuclei at the level of LC (Fig. 1a–d). 
Decreased SSTR2 expression in the LC of Alzheimer’s subjects 
In order to determine the expression-level of SSTR2, micro-punch samples from the LC were 
collected from verified Braak III-IV and V-VI stage subjects and age-matched controls 
(Suppl. Table 2). SSTR2 mRNA expression-levels were high in controls, compared to those of 
galanin (GAL) or galanin receptor 3 (GALR3), members of another inhibitory neuropeptide 
system in LC neurons (Fig. 2a; a higher Ct value reflects a lower expression-level).  
 SSTR2 expression significantly decreased in both Braak III-IV (-48%) and Braak V-VI 
(-45%) groups compared to the age-matched controls. The transcripts for neuron-specific 
microtubule associated protein (MAP2) also decreased significantly in the Braak III-IV group 
(-68%) but, interestingly, its expression-level was improved in the Braak V-VI group (Fig. 
2b).  SSTR2 and MAP2 expressions did not correlate with age, gender or post mortem delay 
(PMD) (data not shown). 
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 No significant changes in transcript levels for TH, the rate-limiting enzyme of 
noradrenaline synthesis, dopamine β-hydroxylase (DBH), GAL or GALR3 were noted in either 
Alzheimer’s groups, compared to age-matched controls. However, a trend towards increase 
both in TH and GALR3 (Fig. 2b) expression was found in the Braak III-IV group.  
 Relative fold-changes for SSTR2 gene expression levels were normalized to β-III-
tubulin (TUBB3) as well as to β-ACTIN and GAPDH with similar results (Fig. 2c, Suppl. 
Table 7).  
Decreased SST immunostaining and aberrant TH-IR fibers in the temporal cortex of 
Alzheimer´s subjects 
Next, we examined the SST immunostaining and the morphology of TH-IR fibers in the 
human brain, with the application of the tissue micro-array (TMA) technique (Fig. 3a). In the 
Alzheimer subjects (Braak V-VI, N=7), dystrophic neurites and neurofibrillary tangles were 
immunostained for tau-PHF throughout the TMA temporal cortex samples and senile plaques 
were stained for amyloid-β (Fig. 4d, g). In contrast, no amyloid-β or tau-PHF staining was 
noted in the controls (with a single exception for amyloid-β) (Fig. 4).  
 In control samples, a dense network of SST-IR processes was strongly immunostained 
(Fig. 4a–b), which was significantly decreased in the Alzheimer’s samples (Fig. 4c–d, g), in 
agreement with previous reports [76]. 
 In both control and Alzheimer’s samples, rare varicose TH-IR fibers with normal 
morphology were immunostained (Fig. 3b–c). In samples from 3 of 10 Alzheimer’s subjects, 
occasional clusters of aberrant TH-IR fiber structures were noted (Fig. 3d–g). These clusters 
were 50-100 µm in diameter, contained loose conglomerates of enlarged-swollen varicosities 
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(Fig. 3e, g), were negative for tau-PHF (Fig. 3d, f) and unrelated to the location of amyloid 
plaques (Fig.3d, f). 
Noradrenergic but not dopaminergic, serotonergic or cholinergic neurons express SSTR2a in 
mouse 
Further experiments were carried out on different Sstr knockout mouse strains and their wild-
type littermates (Suppl. Fig. 1). First, we examined the SSTR2 protein expression of various 
monoaminergic and cholinergic neuron populations. A strong somatodendritic SSTR2a 
staining was seen in the LC and all other examined NA cell groups in Sstr2+/+ (WT) animals 
(A1, A2, A6-LC, A6r and A7; see [26]) (Fig.5a–b), in agreement with a strong ß-
galactosidase immunostaining (sstr2lacZ staining) in the LC neurons of Sstr2-/- (knockout) mice 
(Fig. 5c, upper panel). Importantly, sstr1lacZ or sstr4lacZ staining was never found in the LC NA 
neurons (Fig. 5c, medial, lower panels, respectively). Moreover, serotonergic, dopaminergic 
or cholinergic neurons did not show co-localization with SSTR2a (Fig. 5d).  
Selective noradrenergic axonal degeneration in Sstr2-/- animals 
In Alzheimer’s disease the noradrenergic system shows a marked vulnerability. SSTR2/Sstr2 
is highly expressed in the noradrenergic LC neurons both in human and mouse, and we found 
an early decrease in SSTR2 expression in LC of Alzheimer’s subjects. We therefore examined 
the morphology of the noradrenergic projections of Sstr2-/- mice.  
 The density of fibers positive for NET, DBH and, in many regions also for TH, was 
reduced in 4-month-old Sstr2-/- but not in Sstr1-/- or Sstr4-/- animals (Fig. 6a, c, d). In addition, 
swollen NET+, DBH+ or TH+ fibers and sometimes large aberrant fiber clusters could be 
detected, exclusively in Sstr2-/- animals (Figs. 6a–d, 7, Suppl. Fig. 2 and legends). The fiber 
clusters intermingled with hypertrophic microglial or astroglial cells (Fig. 6b); they co-
localized galanin (Fig. 6c) but were not immunoreactive for β-amyloid (Suppl. Fig. 3). 
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However, morphology and density of fiber networks positive for tryptophan hydroxylase-2 
(TPH2), the dopamine transporter (DAT) or choline acetyltransferase (ChAT) appeared 
normal (Fig. 6d).  
Decreased NA levels in the Sstr2-/- animals 
To validate our morphological data, we then measured levels of monoamines and their main 
metabolites in Sstr2-/- and WT mice. Indeed, NA levels were significantly decreased in the 
fronto-parietal cortex and hippocampus but not in the striatum at 4 months-of-age. In contrast, 
there was no decrease in DA or serotonin levels in any region. At 2 weeks-of-age, NA levels 
were decreased in the hippocampus but not in fronto-parietal cortex or striatum. Serotonin 
levels were not altered at 2 weeks-of-age, but striatal DA levels were slightly increased (Fig. 
6e). 
Morphological, temporal and spatial characterization of noradrenergic axonal degeneration in 
Sstr2-/- mice  
Next, we morphologically and quantitatively/semiquantitatively analyzed the noradrenergic 
degeneration in our knockout model. Fiber aberrations were divided into two categories: 
single swollen varicosities/intervaricose connections and dense clustering of 
aberrant/degenerating fibers (fiber clusters) (Fig. 7 and Suppl. Fig. 2). The single swollen 
varicosities/intervaricose connections were usually 5-7 µm in diameter and exhibited dense 
staining compared with neighboring normal noradrenergic fibers (Fig. 7e*, 7g vs. 7h, Suppl. 
Fig. 2a vs. 2b–c). The knot-like fiber clusters comprised aggregated, irregular-shaped, 
tortuous fibers with a high number of concentrated swollen varicosities/intervaricose 
connections. These clusters were distinct and appeared as an interruption of the adjacent 
normal fiber pattern. Their size varied approximately from 50 to 250 µm (Figs. 7f–f*, 6i–j, 
Suppl. Fig. 2d–k ). 
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Already 1 month postnatally, the TH-IR fiber density in the fronto-parietal cortex was 
significantly decreased compared to the age-matched wild-type mice, and decreased further 
with age (Figs. 7a, 7d–f). However, single, swollen varicosities were apparent already at 2 
weeks-of-age, reaching a maximum at 4 months-of-age and then gradually disappearing (Fig. 
7b). In parallel, aberrant fiber clusters steadily increased until 8 months-of-age (Fig. 7c).   
Signs of degeneration appeared globally in the Sstr2-/- brains, extending from the 
olfactory bulb to the brainstem, being most severe in neocortex, thalamus, amygdala and 
hippocampus. Hypothalamus, the septal region and certain brainstem areas were clearly less 
affected (Table 1). The decrease of NA terminals was also seen in the lumbar spinal cord, 
especially in the dorsal horn, but no aberrant fiber clusters could be detected here (Fig. 8a–b).  
Noradrenergic LC cell bodies do not degenerate in Sstr-/- mice 
 Then, we examined the integrity of LC perikarya to investigate whether the 
noradrenergic degeneration also affected the cell bodies. The number of TH-IR cell bodies 
and their average soma size were not altered in 8-month-old Sstr2-/- mice compared to wild-
type littermates (Fig. 9a–d). However, TH mRNA levels in the LC were modestly decreased 
already at 4 months-of-age (Fig. 9e–g). The expression of the modulatory neuropeptide 
galanin did not change significantly (Fig. 9h).  
Peripheral noradrenergic nerves do not show signs of degeneration  
In order to investigate whether degeneration also affects the peripheral nervous system, we 
examined some peripheral organs well known for a high density of noradrenergic innervation. 
However, NET immunostaining of salivary gland and jejunum samples did not show any sign 
of NA denervation or axonal degeneration (Fig. 10d–f). In agreement, only very few neurons 
exhibited a weak/moderate SSTR2a immunostaining in the superior cervical ganglion, the 
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main source of noradrenergic innervations of peripheral organs in the head region (Figure 
10a–c).  
 
Discussion  
In Alzheimer’s and other neurodegenerative disorders there is a serious noradrenergic 
impairment, including an early and marked degeneration of LC neurons. In the present study 
we show expression of SST receptor subtype-2 protein in noradrenergic LC neurons of 
control human brains, as well as a decrease in levels of its transcript already in the early stage 
of Alzheimer’s disease. Also, the deletion of this single receptor in a mouse model causes an 
early-onset, global, selective and progressive noradrenergic axonal degeneration, most 
distinctly associated with projections from the LC. Serotonergic, dopaminergic and 
cholinergic fibers, however, do not degenerate. This selectivity of impairment for the 
noradrenergic system is confirmed by biochemical analyses. Remarkably, all NA cell groups 
examined, but no 5-HT, DA or cholinergic neurons, express the SST subtype-2 receptor. 
Additional discussion notes are provided in the SI (indicated as ‘SI-D1-3’ in the following). 
Decreased SSTR2 expression in LC in Alzheimer’s disease  
The density of SST binding sites in the LC is very high,  both in the human and rodent brain 
[21]. In agreement, we here show a high mRNA expression level of SSTR2 and a strong 
somatodendritic immunostaining for SSTR2 protein in the human LC. SSTR2 expression was, 
however, significantly decreased already in the early stages of neurodegeneration (with 
intermediate Alzheimer’s disease neuropathological changes, Braak stage III/IV), when 
cognitive impairment but yet no dementia of patients occurs [75]. The LC neurons themselves 
do not express SST, the peptide [67]. According to early experimental studies, the SST 
innervation of  LC mainly originates in the hypothalamus [80], where the SST levels are also 
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decreased in Alzheimer’s subjects, as they are in many cortical regions [76,108]. These 
findings suggest impairment also of the LC-SST system in Alzheimer’s disease. In contrast, 
another inhibitory neuropeptide receptor expressed in the human LC, the GALR3 [62], 
showed even a trend to increase in mRNA concentration in the Braak III-IV stage. The 
expression of MAP2, a dendrite- and soma-specific microtubule associated protein [83] 
decreased in Braak III-IV samples, as expected. However and interestingly, no change in 
MAP2 expression was noted in the Braak V-VI stage, compared to control, which supports a 
previous report on dendritic spouting of remaining LC neurons in the terminal phase of 
Alzheimer’s disease [99]. mRNA expression of TH, the rate limiting enzyme of NA synthesis, 
and of DBH did not decrease, in agreement with previous studies [70,99].   
 Interestingly, LC cell death is either very limited or nonexistent in transgenic mice 
models of Alzheimer’s disease [115]. Thus, in the next part of our study we applied knockout 
mice for different SST receptors (SSTR1, 2, 4) and their wild-type littermates, to further study 
a potential role of SSTR2 signalling in the maintenance of the noradrenergic system. We 
show that Sstr2 is expressed at high levels in all examined noradrenergic nuclei, including 
LC, and also in neocortical areas, while Sstr1 and Sstr4 are expressed in the mouse cortex but 
not in the LC. 
Selective noradrenergic axonal degeneration in Sstr2-/- brains 
The noradrenergic degeneration in Sstr2-/- mice was investigated using immunostainings for 
three noradrenergic markers (TH, NET, DBH), and galanin [100], the latter a neuropeptide 
expressed in LC neurons [71]. In contrast, no degenerative features in serotonergic, 
dopaminergic or cholinergic fibers were found, further underlining the selectivity of this 
degenerative process for the noradrenergic system, also supported by the HPLC regional 
measurements of NA, 5-HT and DA. 
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All three noradrenergic markers showed enlarged/swollen varicosities/intervaricose 
connections and clusters of aberrant fibers, in parallel with a substantial decrease of fiber 
densities. Such features have already been reported for serotonergic and cholinergic systems 
in normal, aging rats [7,110,77,3], as well as in the entire monoaminergic system of Zitter 
mutant or microenchephalic rats [106,114]. Enlarged/swollen varicosities are generated by 
accumulations of intra-axonal materials as a result of impaired axonal transport due to 
destabilization of microtubules. The knot-like fiber clusters are formed following the gradual 
degeneration of intervaricose connections [110,109,4].    
The noradrenergic, axonal degeneration in Sstr2-/- animals is global, starts early and 
gradually progresses with the first distinct appearance of enlarged varicosities at around 2 
weeks-of-age, followed by a gradual cluster formation from 2 months-of-age (SI-D1). The 
decrease of NA levels in general parallels the loss of noradrenergic terminals (SI-D2). 
However, the LC cell bodies seem morphologically preserved with only a modest decrease of 
TH mRNA levels, in any case up till 8 months-of-age, suggesting that the degeneration in 
Sstr2-/- animals primarily affects the axons. However, there was no evidence for degenerative 
processes in the peripheral noradrenergic sympathetic nerves/axons [78], nor in dopaminergic, 
serotonergic or cholinergic neurons, which all lacked SSTR2 immunostaining, except for a 
few cells in the superior cervical ganglion. Neither was degeneration detected in the 
noradrenergic projections of Sstr1-/- and Sstr4-/- mice, and sstr1LacZ or sstr4LacZ staining, 
respectively, was never found in the brainstem NA cells of these knockouts.  
Possible mechanisms underlying the noradrenergic axonal degeneration in Sstr2-/- mice  
Disturbed development/trophism  
There is evidence that SST has trophic effects on neurite outgrowth [38,37].  Our previous 
results on dorsal root ganglia indicate that a SST-SSTR2a complex can be retrogradely 
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transported [95], perhaps mediating intracellular, trophic effects in a similar way as nerve 
growth factor (NGF) [63]. Thus, one explanation might be that absence of SSTR2 prevents 
retrograde transport of SST required for proper maintenance and development of intact NA 
axons and nerve terminals.  
Attenuated somatodendritic inhibition and dysfunctional stress axis  
SST receptors dampen the stress system [96], of which the LC is an important node (see 
Introduction). ACTH levels were previously found to be increased in Sstr2 knockouts [113]. 
The LC neurons express Sstr2 at high levels from the embryonic age till adulthood [101], and 
the postsynaptic SSTR2 mediates a strong inhibitory action of SST on spontaneous firing of 
LC neurons [23]. Our results confirm that LC neurons and all examined NA cell groups 
express a strong somatodendritic but no detectable axonal SSTR2 immunostaining postnatally 
in mouse; and these are the neuron groups associated with axonal degeneration. We 
hypothesize that the chronic absence of somatodendritic SSTR2-mediated inhibition of NA 
neurons leads to a continuous overexcitation and a slow, selective degeneration/accelerated 
aging of noradrenergic axons due to oxidative stress.  
Aberrant TH-IR fibers in the temporal cortex of Alzheimer´s subjects 
 Despite the well-established neuronal cell body loss in LC, we do not know of any 
comprehensive studies on the morphology of noradrenergic axonal arborization in 
Alzheimer’s disease. Nevertheless, NA levels [2,81] and DBH activitity [25] are decreased in 
Alzheimer’s frontal-temporal cortical samples, supporting loss of NA fibers. 
 Using TMA slides, we showed clusters of apparently aberrant TH-IR fibers with 
enlarged varicosities from some terminal-phase Alzheimer’s subjects, which were similar in 
morphology and size to the degenerating noradrenergic fiber clusters found in Sstr2-/- mice. 
However, in addition to noradrenergic fibers, TH also labels a substantial number of 
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dopaminergic fibers in the human neocortex [43]. More advanced fixation techniques [43], 
allowing the application of the DBH or NET antibodies to human brain, are required for the 
detailed morphological and quantitative spatial analysis of noradrenergic axonal arborization 
in human post mortem brain samples from neurodegenerative diseases.  
The behavioral phenotype of Sstr2-/- mice 
Sstr2 knockout/LacZ knockin mice show impaired motor coordination [6], and another Sstr2 
knockout strain exhibits locomotor and exploratory deficits, as well as enhanced anxiety-like 
behavior (SI-D3). Moreover, enhanced glutamate transmission in the hippocampus of young 
Sstr2 knockouts was described [31,113], perhaps due to reduced SST-mediated inhibition of 
glutamate release [33].  
This Sstr2-/- behavioral phenotype is comparable with a dysfunctional noradrenergic 
system. Thus, DBH-/- mice show deficits in social discrimination, reduced exploratory activity 
in novel environments, decreased locomotor activity in novel stimulation and impaired motor-
coordination [66,86]. Moreover, rats with axonal NA degeneration after treatment with the 
neurotoxin DSP4 exhibit neophobic behavior [50], very much resembling the Sstr2-/- 
behavioral phenotype.  
Implications for neurological and mental disorders 
 SST was found to be the most consistently reduced neuropeptide in Alzheimer’s 
disease [20,27,89,58,19]. The SST deficit correlates well with the dementia score in 
Alzheimer’s disease but less so with progression of neuropathology [30], indicating 
association mainly with cognitive impairment [112,34].  
Pre-clinical and clinical trials have indicated that a SST release-enhancer (FK962) or 
the SST analogue octreotide (sandostatin) improves memory [24,102], but finally none of 
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them passed the phase 3 trial. Recent pre-clinical studies, however, reported that FK962 
combined with the AChE inhibitor donepesil (Aricept) has a significantly greater effect on 
cognition than either compound alone [69]. This supports the notion on the necessity of 
combined therapy of Alzheimer’s disease, a multisystem disorder affecting multiple neuronal 
population [29]. 
Several clinical and experimental studies indicate that the SST system is also 
implicated in stress, anxiety and depression [64], and there is now direct evidence that, in fact, 
the receptor involved is SSTR2 [32,33,118]. Notably, depression is a leading neuropsychiatric 
complication in Alzheimer’s disease [94], and an association with chronic life stress and later-
life cognitive dysfunction has been proposed [46]. 
Concluding remarks  
The main goal of our studies was to elucidate potential factors underlying the well 
documented vulnerability of the noradrenergic LC neurons in Alzheimer’s disease. It has been 
proposed that the evolutionary fast and large increase in brain volume, including the 
expansion of the long and poorly myelinated diffuse cortical projections of subcortical nuclei, 
such as LC, have made these evolutionary old, subcortical structures more vulnerable to age-
related challenges specifically in the human brain [14,15]. Consequently, the currently used 
Alzheimer mouse models do not appear suitable for the study of pathomechanisms 
responsible for neurodegeneration of the LC in Alzheimer’s disease. Therefore, we turned to 
another experimental approach based on the facts that (i) SST is significantly decreased in the 
cortex and hypothalamus in Alzheimer’s disease, and (ii) one of its receptors, the SSTR2, is 
highly expressed not only in rodent but also, as shown here, in the human LC.  
The present findings of an early, selective and global axonal degeneration of 
noradrenergic projections in Sstr2-/- mice suggest that SSTR2 is critically involved in the 
maintenance and integrity of noradrenergic system, a widespread brain network of 
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fundamental importance for the regulation of arousal, stress and emotions, memory functions 
and motor coordination. Based on these animal data, we propose that an early decrease of 
SSTR2 expression in the LC of Alzheimer’s disease subjects, in agreement with the present 
results on Alzheimer brains, may be an important component of the vulnerability of LC 
projections. Our data supports a scenario in which reduced SST neurotransmission and 
SSTR2 receptor mediated signaling in noradrenergic LC neurons contributes to the loss of 
noradrenergic innervation of the forebrain in Alzheimer’s disease. Noradrenergic impairment 
results in mood and other behavioral changes and accelerates AD pathology as shown by 
others [98,52,48,85]. Finally, our results point to the SSTR2 as potential drug target for 
neurodegenerative and/or neuropsychiatric disorders, perhaps as part of a combined 
pharmacotherapy. 
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Figure legends 
Fig. 1 Somatodendritic SSTR2a immunolocalization in human LC. (a) Low-power overview 
of human LC (TH+SSTR2a double labeling). (b) Schematic representation of the dorsolateral 
part of human brainstem at the level of Obex +23, adopted from the human brainstem atlas of 
Paxinos and Huang [82]. The box in B shows area depicted in A. (c) Higher magnification of 
the boxed zone c in panel A. Note the somatodendritic localization of SSTR2a in several TH-
IR NA LC neurons (arrowheads). (d) High magnification of the boxed zone d in panel A. 0.5-
µm-thick optical layer micrograph of an individual neuron, confocal microscopy. 4V: fourth 
ventricle; me5: mesenchephalic trigeminal tract. Scale bars: 400 µm in a; 100 µm in c; 10 µm 
in d. 
Fig. 2 Decreased SSTR2 expression in the LC in Alzheimer’s disease (AD). (a) Average Ct 
values of control cases for all examined genes. SSTR2 is expressed at levels almost as high as 
for TH, compared to GAL and GALR3, the most abundant galanin receptor in LC [62]. Note 
that the Ct values are inversely proportional with the amount of detected RNA. (b) The 
expression level of SSTR2 is significantly decreased in Alzheimer’s disease Braak III-IV and 
V-VI stages. MAP2 expression is decreased only in the Braak III-IV stage. Relative 
expression levels (fold changes) were calculated by normalizing Ct values to TUBB3 as a 
reference gene and subsequently to the average of controls. Fold-changes were calculated by 
the comparative Ct method (2-∆∆CT).  Values for controls were set to 1.00. (c) Relative 
expression level of SSTR2, where Ct values were normalized to TUBB3, ACTIN or GAPDH as 
reference genes. Statistical analysis: one-way ANOVA and Fisher Test for post-hoc test for 
comparisons (N=8, N=5, N=7, control, AD Braak III-IV, AD Braak V-VI, respectively; 
*significant difference between control and AD cases, #significant difference between AD 
Braak III-IV and AD Braak V-VI cases). Data are expressed as mean + SEM. 
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Fig. 3 Aberrant TH-immunoreactive fibers in the temporal cortex of Alzheimer’s disease 
brains (a) Tissue micro-array (TMA) slide with 1-mm-diameter temporal cortical punch 
samples of 7 Alzheimer’s disease subjects (in squared boxes) and 9 control subjects. (The 
TMA slide also contained 10 DLB cases, which were not analyzed in the present study). The 
slides were triple-stained for TH, amyloid-β and Tau-PHF and were counterstained with the 
nuclear staining DAPI. Whole slide immunofluorescence for Tau-PHF (AT8) is 
demonstrated. (b–c) Examples of morphologically intact TH-IR fibers from an age-matched 
control case (arrowheads). The boxed zone in b is enlarged in c. Note that there is no any 
amyloid-β or tau PHF immunostaining in the control tissue.  (d–g) Examples of aberrant, 
cluster-like TH-IR structures containing swollen varicosities from two Alzheimer’s frontal 
cortex samples (AD brain 1 and 2) are shown. Dystrophic neurites are immunostained for tau-
PHF throughout the samples (d, f) and amyloid plaques are stained for amyloid-β (d, stars). 
The boxed fiber clusters in d and f (triple staining) are enlarged in e and g, respectively (TH 
staining only). Scale bars: 2,000 µm in a; 50 µm in b, d and f; 25 µm in e and g, 20 µm in c. 
Fig. 4 Immunohistochemical staining of Alzheimer and control brains in temporal cortex 
samples. (a–d) Representative micrographs from a tissue micro-array slide triple-stained for 
SST, amyloid-β and Tau-PHF and counterstained with Dapi. In the control sample, a dense 
network of SST-IR processes was strongly immunostained (a-b). In the Alzheimer samples, 
SST-like immunoreactivity significantly decreased: only sparse fibers were noted throughout 
the samples (c-d). In contrast, amyloid-β IR depositions and tau-PHF IR dystrophic neurits 
and neurofibrillary tangles (* in d) were frequently noted in the AD samples but not in the 
control samples (c-d vs. a-b). Arrows in d indicate tau-PHF+ dystrophic neurites/terminals 
around the amyloid-β+ senile plaques. Boxed zones in a and c are enlarged in b and d, 
respectively. Scale bars: 100 µm in c applies for a and c; 50 µm in d, applies for b and d.  (e–
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g) Quantitative evaluation of SST, amyloid-β and tau-PHF immunoreactivity in the TMA 
slide (densitometry analysis). Note that the immunoreactivity for amyloid-β (e) and tau-PHF 
(f) significantly increases, while the SST-like immunoreactivity significantly decreases (g) in 
the Alzheimer’s samples. Statistical analysis: Student’s t-test for independent samples (N = 7 
and 9, Alzheimer’s disease and control samples, respectively).  
Fig. 5 SSTR2a protein expressions in mouse NA cell groups. (a–b) Noradrenergic neurons in 
the LC (a, low power overview; a*, high power micrographs) and all other examined NA cell 
groups (A1, A2, A6r, A7, panel b) exhibit prominent somatodendritic SSTR2a localization. 
(c) Strong sstr2lacZ staining in the LC neurons of Sstr2-/- mice (upper panels). No NET-IR 
(noradrenergic) neurons co-localize with Sstr1lacZ or with Sstr4lacZ staining in the LC of Sstr1-/- 
or Sstr4-/- animals, respectively (medial and lower panels, respectively). (d) TPH2-IR 
(serotonergic) neurons in the dorsal raphe, DAT-IR (dopaminergic) neurons in the substantia 
nigra pars compacta and VTA and ChAT-IR (cholinergic) neurons in the nucleus basalis 
Meynerti or in the nucleus of the horizontal limb of the diagonal band (HDB) do not show co-
localization with SSTR2 in WT animals. Scale bars: 100 µm in a and c; 10 µm in a*; 50 µm in 
b and d. 
Fig. 6 Selective noradrenergic axonal degeneration in Sstr2-/- animals. (a) Sstr2-/-, but not 
Sstr1-/- or Sstr4-/- mice exhibit a substantially reduced density of TH-IR nerve terminals in the 
prefrontal cortex (FCtx). Aberrant large fiber clusters are also often detected (arrows). (b) The 
large TH-IR fibers clusters (arrows) are associated with activated microglial (Iba1-IR) or 
astroglial (GFAP-IR) cells. In contrast, astroglial or microglial cells exhibit normal 
morphology in WTs. (c) The noradrenergic marker DBH shows a reduced density of 
noradrenergic fibers, many of them with swollen profiles and cluster formations (left panel). 
Aberrant noradrenergic fibers and fiber clusters (arrows) are co-localized with the 
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neuropeptide galanin, known to be expressed in cortical and hippocampal noradrenergic fibers 
(and LC) [116]. (d) Serotonergic (TPH2-IR, FCtx), dopaminergic (DAT-IR, insular cortex) or 
cholinergic (ChAT-IR, FCtx) fibers do not show any signs of degeneration in Sstr2-/- mice, 
contrasting the noradrenergic fibers (NET, FCtx). (e) HPLC measurements of monoamine 
neurotransmitters (NA; DA; 5-HT) in 2-week- and 4-month-old Sstr2-/- and WT mice. NA 
levels were significantly decreased in the FCtx and hippocampus (Hippo) but not in the 
caudate-putamen (CPu) of 4-month-old Sstr2-/- mice. In the 2-week-old Sstr2-/- mice, there 
was a significant decrease in NA levels only in the Hippo and a slight but yet significant 
increase in the DA levels of CPu. Other monoamine levels were not significantly altered. 
Statistical analysis: three-way analysis of variance (ANOVA, variables: region, genotype, 
age) and Tukey Test for post-hoc comparisons (N = 5, *P < 0.05; #P < 0.1, trend to 
significance). Data are expressed as mean + 
Fig. 7 Detailed characterization of selective noradrenergic axonal degeneration. (a) The TH-
IR fiber density is gradually decreased with age in the frontal cortex of Sstr2-/-, compared to 
age-matched WTs. Statistical analysis: two-way analysis of variance (ANOVA, variables: 
genotype, age) and Tukey Test were used for post-hoc comparisons (N = 4, *P < 0.05). Data 
are expressed as mean 
SEM. Scale bars: 100 µm in a, b and in c left 
panel; 50 µm c right panel; 200 µm in d. 
+ SEM. (b–c) Single swollen varicosities/intervaricose connections 
and dense clustering of fibers with irregular fiber pattern (fiber clusters) were quantitatively 
determined in the fronto-parietal cortex of TH immunostained sections of Sstr2-/- mice. 
Statistical analysis: one-way ANOVA and Tukey Test for post-hoc comparisons (N = 4, *P < 
0.05). Data are expressed as mean + SEM. (d–f, d*–f*) Overview of morphological 
alterations in the noradrenergic system of Sstr2-/- animals. The noradrenergic fiber density 
gradually decreases, while the number of aberrant fiber structures (swollen, enlarged 
varicosities, arrowheads in e*; fiber clusters, arrowheads in f–f*) gradually increases with 
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age. d, e, f: low power overviews of somatosensory-parietal-retrosplenial cortices; d*, e*, f*: 
higher magnification micrographs from somatosensory cortex. (g–j) Confocal analysis of 
aberrant noradrenergic structures (merged micrographs of 0.5-µm-thick optical layers along 
the Z-stack). The single swollen varicosities/intervaricose connections (5-7 µm in diameter; h, 
arrows) are easily identifiable due to their morphology and dense staining compared with 
neighboring normal noradrenergic fibers (g). The knot-like fiber clusters (‘loose type’, i; 
‘compact’, j) comprise aggregated, irregular-shaped, tortuous fibers with a high number of 
concentrated swollen varicosities/intervaricose connections. These clusters are distinct and 
appear as an interruption of the adjacent normal fiber pattern. Their size varied approximately 
from 50 to 250 µm. The single swollen varicosities/intervaricose connections and the distinct 
fiber clusters are visualized in the same manner using antibodies to NET, TH or DBH. These 
aberrant structures are virtually not detected in the WTs. Scale bars: 500 µm in d, applies to d, 
e and f; 100 µm in f*, applies to d*, e* and f*; 25 µm in g, applied to g and h; 100 µm in i, 
applies to i and j. 
Fig. 8 Distinct loss of noradrenergic fibers in the spinal cord. There is a marked decrease of 
the NET-IR fiber density in the lumbar spinal cord of a 4-month-old Sstr2-/- animal compared 
to WT (cf. b with a), but no large fiber clusters can be seen. The most pronounced fiber 
decrease is found in the dorsal horn (Rexed laminae I-IV). A moderate decrease is detected in 
Rexed laminae V-VIII. No apparent decrease in degeneration/fiber density is detected in 
Rexed X (around the central canal) or Rexed IX. CC: central canal. Scale bar: 200 µm in a 
applies to a and b. 
Fig. 9 No signs of degeneration of LC cell bodies can be detected in Sstr2-/- mice up till 8 
months-of-age. (a–b) TH immunostaining (FITC - green) and TO-PRO®-3 (far red, 
transformed digitally to red color) nuclear counterstaining of the LC from an 8-month-old WT 
(a) and a Sstr2-/- (b) mouse. (c–d) The number of TH-IR cell bodies and also their mean 
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somatic surface area do not show significant differences between the 8-month-old Sstr2-/- and 
their age-matched WT littermates. (e–f) TH in situ hybridization in 4-month-old WT (e) and 
Sstr2-/- (F) LC. (g–h) Summary of quantitative results from 4-month-old animals. TH, but not 
galanin expression is decreased in the Sstr2-/- compared to WT mice. Statistical analyses: 
Student’s T-test for independent samples (N = 3, N = 5, c-d, g-h, respectively. *P < 0.05). 
Data are expressed as mean + 
Fig. 10 There is no noradrenergic degeneration in the peripheral nervous system. TH (a) 
neuropeptide Y (NPY, b) and SST2a (c) immunostaining of the superior cervical ganglion 
(SCG) of a WT animal is demonstrated. Note that the faint-moderate SST2a immunoreactivity 
in SCG is restricted only to a few neurons. NET immunostaining of jejunum (d-e) and 
salivary gland (f-g) of Sstr2-/- (e, g) and WT (d, f) littermates. No signs of axonal degeneration 
are found in the peripheral noradrenergic system. Scale bars: 200 µm in a, applies to all 
panels. 
SEM. Scale bar: 100 µm in a, applies to a, b, e and f. 
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Table 1 Semiquantitative score of degenerative fiber processes in Sstr2-/- mice. The score is 
based on NET (noradrenaline transporter) immunohistochemistry (average of scores obtained 
from 4-month-old (N = 3) and 8-month-old (N = 3) Sstr2-/- mice brains. 0 = no apparent sign 
of degeneration; + = no cluster, few individual swollen varicosities; ++ = few clusters, many 
individual swollen neurites; +++ = many clusters, many individual swollen neurites. The 
descriptions of ‘fiber cluster’ and ‘individual swollen neurite’ are provided in the Results 
(Figure 6, Figure S3, legends). 
 
Brain region nucleus/subregion 
4 months 
(N = 3) 
8 months 
(N = 3) 
Bulbus 
 
 + + - ++ 
Cerebral cortex prefrontal Ctx (dorsal peduncular, infralimbic) 
  
++ +++ 
 cingulate ctx 1-2 ++ +++ 
 motor ctx 1-2. ++ +++ 
 primary somatosensory ctx 1. ++ ++ 
 primary somatosensory ctx – barrel/upper lip region & 
secondary somatosensory ctx 
++ ++ - +++ 
 agranular insular – disgranular ctx ++ - +++ +++ 
 piriform ctx +  - ++ ++ 
 retrosplenial ctx + - ++ +++ 
 visual ctx ++ ++ 
 auditory ctx ++ ++ 
 entorhinal ctx ++ +++ 
 caudomedial entorhinal ctx ++ +++ 
Septal region  + + 
Thalamus anteroventral thalamic nucleus ++ - +++ +++ 
 ventral thalamic nuclei ++ +++ 
 nuclei geniculatae + ++ 
Hypothalamus preoptic region ++ + - ++ 
 anterior hypothalamus + + - ++ 
 ventromedial hypothalamic nucleus + 0 - + 
 dorsomedial hypothalamic nucleus + + 
 perifornical lateral hypothalamus + + 
Amygdala basal amygdala ++ - +++ +++ 
Hippocampus rostral hippocampus ++ ++ - +++ 
 dorsal hippocampus ++ ++ - +++ 
 ventral hippocampus ++ +++ 
 area amygdalahippocampalis ++ +++ 
Brainstem periaqueductal gray matter + + - ++ 
 dorsal raphe 0 - + + 
 colliculus inferior + ++ 
 locus coeruleus dendrites 0 0 
 b ll       
